RFA-CA-21-063: A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials (CUSP2CT; U01 Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2021.
National Institutes of Health offered grants of up to $450,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on December 10, 2021.
From the official notice on Grants.gov, last changed October 21, 2021. Checked November 7, 2026.
- Award ceiling$450,000
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU01
- Clinical trialsOptional
- Funded byNCI
- Median yearly award$704,063
- Typical project length5 years
- U01, Research Project Cooperative Agreement. Like an R01, but NIH staff are substantially involved in the work. Other open U01 notices.
Projects funded under RFA-CA-21-063 were run by National Cancer Institute (NCI, 4 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-CA-21-063 in the NIH Guide.
Key dates
| Posted | October 19, 2021 |
|---|---|
| Deadline | December 10, 2021 |
| Archived by Grants.gov | January 15, 2022 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $704,063; it allows up to $450,000 per award.
- Most of the program's money (57% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) solicits applications for Connecting Underrepresented Populations to Clinical Trials (CUSP2CT), a program that will implement and evaluate multilevel and culturally tailored outreach and education interventions with the primary goal of increasing referral and ultimately, accrual of underrepresented racial/ethnic (R/E) minority populations, to NCI-supported clinical trials (CTs) (National Clinical Trial Network (NCTN), NCI's Community Oncology Research Program (NCORP), and Experimental Therapeutics Clinical Trials Network (ETCTN)). The target population(s) should include individuals from underrepresented racial/ethnic (R/E) minority populations. Applicants should address cancer health disparities (CHD) through a network of local multidisciplinary and integrated partners that include community health educators (CHEs), lay health advisors (LHAs), community members, healthcare providers, and researchers working in coordination to educate and refer R/E minority populations to NCI-supported CTs, and increase awareness in providers about R/E minority participation in NCI clinical trials. This will require outreach and education multilevel interventions at the CT site, provider, and/or patient levels. The proposed interventions should be informed by relevant theories, frameworks, or models and guided by preliminary data and/or the sufficient infrastructure in place and expertise on the local contextual barriers and facilitators for increasing CT referral of R/E minority population. It is expected that U01 grantees will establish partnerships with the community, primary care providers, and other stakeholders to enhance identification of R/E minority referral barriers and facilitators to NCI-supported CTs. A companion funding opportunity (see U24 funding opportunity RFA-CA-21-058) will support a Data, Evaluation and Coordinating Center (DECC) that will provide experienced project
Funded under RFA-CA-21-063 so far
NIH funded 4 projects under RFA-CA-21-063 in fiscal 2022 to 2026, at 4 institutions. The median yearly award was $704,063.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| The ECOG-ACRIN SUPPORT Trial: Multilevel Intervention to Improve Diverse Enrollment in Cancer Clinical Trials | Ecog-Acrin Medical Research Foundation | 2026 | $629,017 |
| A Multi-level Approach to Connecting Individuals to Cancer Clinical Research | Mayo Clinic Jacksonville | 2026 | $857,840 |
| Advancing Clinical Trials: Working through Outreach, Navigation and Digital Enabled Referral and Recruitment Strategies (ACT WONDERS) | H. Lee Moffitt Cancer Ctr & Res Inst | 2025 | $1.5 million |
| OSUCCC CUSP2CT | Ohio State University | 2025 | $1.4 million |
Who has won Cancer Treatment Research grants before
From fiscal 2021 to 2025, Cancer Treatment Research (93.395) awarded $5.6 billion across 3,622 grant awards, an average of $1.5 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 144 | $188 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 68 | $185 million |
| Icahn School of Medicine at Mount Sinai | New York | 35 | $179 million |
| Public Health Institute | California | 4 | $168 million |
| Fred Hutchinson Cancer Center | Washington | 57 | $156 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-CA-21-063 still open?
No. It closed on December 10, 2021.
Who can apply for A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials (CUSP2CT; U01 Clinical Trial Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials (CUSP2CT; U01 Clinical Trial Optional)?
Closed December 10, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $450,000 each.
Who has been funded under RFA-CA-21-063?
NIH RePORTER lists 4 projects funded under RFA-CA-21-063 in fiscal 2022 to 2026, at 4 institutions. The most were at Ecog-Acrin Medical Research Foundation, Mayo Clinic Jacksonville, H. Lee Moffitt Cancer Ctr & Res Inst.
Who has won Cancer Treatment Research grants before?
The largest recipients over five fiscal years were The Univeristy of Texas M.D. Anderson Cancer Center, Dana-Farber Cancer Institute, Inc., Icahn School of Medicine at Mount Sinai. The program made 3,622 awards worth $5.6 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Single Source for the Continuation of the Physiology of the Weight Reduced State (POWERS) Study (U01- Clinical Trials Required)
- Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
- Opportunities for Collaborative Research with the NIH Intramural Research Program (U01 Clinical Trial Optional)